No connection

Search Results

WVE

BEARISH
$7.31 Live
Wave Life Sciences Ltd. · NASDAQ
Target $24.93 (+241.1%)
$5.02 52W Range $21.73
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$1.38B
P/E
N/A
ROE
-55.0%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.

Key Strengths

Very low Debt/Equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.47)
High analyst target price ($24.93) suggesting potential clinical catalysts
Low overall leverage reducing immediate bankruptcy risk
Positive 3-year price trajectory despite recent volatility

Key Risks

Severe revenue contraction (-79.4% YoY)
Extreme operational inefficiency (Operating Margin -327.44%)
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)
Aggressive insider selling by C-suite executives
Sharp technical breakdown with a 37% decline in the last month

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
20
Weak
Value
10
Future
30
Past
20
Health
40
Dividend
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score 1/9, Revenue collapse, Insider divestment, Extreme P/S ratio
Confidence
90%
Value
10/100

Ref P/E N/A, P/S 32.21, Graham Number None

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 32.21 is unsustainable given revenue trends
  • No earnings to support a Graham Number
Future
30/100

Ref Revenue Growth -79.40%

Positives
  • Strong analyst price targets suggest future pipeline potential
Watchpoints
  • Revenue growth is deeply negative (-79.4%)
  • Earnings surprises are consistently negative
Past
20/100

Ref 1M Change -37.1%

Positives
  • Long term 3Y growth was positive
Watchpoints
  • Recent 1-month price crash of 37.1%
  • Poor earnings track record over last 4 quarters
Health
40/100

Ref Piotroski F-Score 1/9, Current Ratio 6.47

Positives
  • High Current Ratio (6.47)
  • Very low Debt/Equity (0.03)
Watchpoints
  • Piotroski F-Score 1/9 indicates fundamental deterioration
  • Negative ROE and ROA
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • Zero payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$7.31
Analyst Target
$24.93
Upside/Downside
+241.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for WVE and closest competitors.

Updated 2026-04-23
WVE
Wave Life Sciences Ltd.
Primary
5Y
+16.6%
3Y
+81.8%
1Y
+7.7%
6M
+3.7%
1M
-37.1%
1W
-0.1%
NVC
NovoCure Limited
Peer
5Y
-93.7%
3Y
-81.1%
1Y
-26.1%
6M
-14.2%
1M
-1.7%
1W
+12.8%
HCS
Healthcare Services Group, Inc.
Peer
5Y
-32.6%
3Y
+36.6%
1Y
+106.5%
6M
+16.8%
1M
-0.9%
1W
+1.7%
PGE
Precigen, Inc.
Peer
5Y
-46.5%
3Y
+240.5%
1Y
+188.3%
6M
+13.2%
1M
+11.6%
1W
-7.5%
IMT
Immatics N.V.
Peer
5Y
-10.0%
3Y
+69.3%
1Y
+162.7%
6M
+0.7%
1M
+4.0%
1W
+0.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-5.46
PEG Ratio
N/A
P/B Ratio
2.65
P/S Ratio
32.21
EV/Revenue
18.72
EV/EBITDA
-3.77
Market Cap
$1.38B

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -327.44%
Gross Margin N/A
ROE -54.97%
ROA -27.18%

Growth

Revenue and earnings growth rates

Revenue Growth -79.4%
Earnings Growth N/A
Q/Q Revenue Growth -79.41%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.03
Low debt
Current Ratio
6.47
Strong
Quick Ratio
6.35
Excellent
Cash/Share
$3.2

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-327.4%
Net Margin
-308.4%
Total Assets
$0.6B
Liabilities
$0.1B
Equity
$0.5B
Debt/Equity
0.23x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-28
$N/A
2026-02-26
$-0.3
-13.5% surprise
2025-11-10
$-0.32
-8.2% surprise
2025-07-30
$-0.31
-9.0% surprise

Healthcare Sector Comparison

Comparing WVE against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)
Return on Equity (ROE)
-54.97%
This Stock
vs
-92.94%
Sector Avg
-40.9% (Below Avg)
Debt to Equity
0.03
This Stock
vs
2.75
Sector Avg
-98.8% (Less Debt)
Revenue Growth
-79.4%
This Stock
vs
131.76%
Sector Avg
-160.3% (Slower)
Current Ratio
6.47
This Stock
vs
4.62
Sector Avg
+39.9% (Stronger)

Similar Companies

Peer comparison within the same industry

WVE Wave Life Sciences Ltd.
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-55.0%
Price
$7.31
NVCR NovoCure Limited
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-38.9%
Price
$12.17
 Compare with WVE
HCSG Healthcare...
BULLISH
Mkt Cap
$1.4B
P/E
23.9
ROE
11.7%
Price
$19.35
 Compare with WVE
PGEN Precigen, Inc.
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-572.0%
Price
$3.95
 Compare with WVE
IMTX Immatics N.V.
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-37.1%
Price
$10.43
 Compare with WVE

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

RA CAPITAL MANAGEMENT, L.P.
Beneficial Owner of more than 10% of a Class of Security
Buy
2026-03-30
8,772,496 shares · $54,624,378
TAKANASHI KEN
Director
Stock Award
2026-03-23
3,901,348 shares
FRANCIS CHRISTOPHER JOHN
Officer
Sell
2026-02-26
33,194 shares · $499,593
FRANCIS CHRISTOPHER JOHN
Officer
Option Exercise
2026-02-26
33,194 shares · $141,920
MORAN KYLE
Chief Financial Officer
Sell
2026-02-09
3,588 shares · $48,259
BOLNO PAUL B. M.D.
Chief Executive Officer
Sell
2026-02-09
10,480 shares · $140,956
VARGEESE CHANDRA
Officer
Sell
2026-02-09
3,228 shares · $43,417
FRANCIS CHRISTOPHER JOHN
Officer
Sell
2026-02-09
1,883 shares · $25,326
MORAN KYLE
Chief Financial Officer
Stock Award
2026-02-05
45,625 shares
BOLNO PAUL B. M.D.
Chief Executive Officer
Stock Award
2026-02-05
165,000 shares
VARGEESE CHANDRA
Officer
Stock Award
2026-02-05
45,625 shares
FRANCIS CHRISTOPHER JOHN
Officer
Stock Award
2026-02-05
38,750 shares
FRANCIS CHRISTOPHER JOHN
Officer
Sell
2026-01-02
9,375 shares · $150,260
FRANCIS CHRISTOPHER JOHN
Officer
Option Exercise
2026-01-02
9,375 shares · $29,438
GSK PLC
Beneficial Owner of more than 10% of a Class of Security
Buy
2025-12-11
1,470,000 shares · $27,930,000
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-21
8-K
8-K
2026-04-15

Wave Life Sciences filed a current report on April 15, 2026, to disclose a material corporate event.

8-K
8-K
2026-03-26
10-K
10-K
2026-02-26

WVE filed its annual 10-K report on February 26, 2026, detailing its business operations, financial condition, and results of operations. The filing includes comprehensive disclosures regarding the company's strategic business direction and associated risk factors.

8-K
8-K
2026-02-26

Wave Life Sciences likely reported its fourth-quarter and full-year financial results in this 8-K filing.

8-K
8-K
2026-02-02

Wave Life Sciences filed an 8-K on February 2, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K
8-K
2026-01-12
8-K
8-K
2025-12-11
8-K
8-K
2025-12-08
8-K
8-K
2025-11-17
10-Q
10-Q
2025-11-10
8-K
8-K
2025-11-10
8-K/A
8-K/A
2025-10-30
8-K
8-K
2025-10-29
8-K
8-K
2025-09-24
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
15 analysts
HC Wainwright & Co.
2026-04-14
Maintains
Buy Buy
B of A Securities
2026-03-27
Maintains
Buy Buy
Wells Fargo
2026-03-27
Maintains
Overweight Overweight
Mizuho
2026-03-25
Maintains
Outperform Outperform
Canaccord Genuity
2026-03-10
Maintains
Buy Buy
Wedbush
2026-03-06
Maintains
Outperform Outperform
HC Wainwright & Co.
2026-03-02
reit
Buy Buy
Wells Fargo
2026-02-12
Maintains
Overweight Overweight
Cantor Fitzgerald
2026-02-05
Maintains
Overweight Overweight
Canaccord Genuity
2026-02-03
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning WVE from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile